CellFE’s gene editing workflows are tailored for various cell types to offer unparalleled benefits with no optimization delays. Our technology enhances editing efficiency, preserves cell functionality, and ensures consistent complex gene modifications – accelerating your path to therapeutic breakthroughs.
Breaking Bottlenecks, Building Breakthroughs
OPTIMIZATION
OPTIMIZATION
FULLY OPTIMIZED WORKFLOWS
Ensures consistent, uniform payload delivery across a variety of cell types via pre-optimized workflow parameters.
PERFORMANCE
PERFORMANCE
BEST-IN-CLASS PERFORMANCE
Achieves highest editing efficiency across a range of genetic payloads with preserved cell health and functionality.
EFFICIENCY
EFFICIENCY
COST REDUCTION
Eliminates the need for specialized buffers and reagents while also shortening workflow timelines.
INTEGRATION
INTEGRATION
SEAMLESS INTEGRATION
Easy-to-use system that adapts to any lab or manufacturing protocol with no optimization required for scale-up.
IPSC
CellFE’s cGMP-compatible workflow for induced pluripotent stem cell (iPSC) gene editing redefines efficiency and reliability in cell therapy development. Leveraging the Ryva™ System—a novel, non-viral, microfluidic-based technology—the workflow enables the delivery of even large genetic payloads into iPSCs with unmatched precision and minimal cell stress.
HSC
cGMP-compatible workflows for hematopoietic stem cell (HSC) gene editing redefine efficiency and scalability in cell therapy manufacturing. Leveraging the Ryva™ System, the CellFE HSC workflow delivers gene editing payloads with exceptional precision, preserving high cell viability (>85–90%), superior cell recovery, and minimal cellular stress. The result is unmatched flexibility and reliability for clinical-grade HSC therapies.
T Cell
CellFE offers versatile workflows for both activated and resting T cells, providing unparalleled flexibility and control in your cell therapy manufacturing. Our optimized processing enables efficient gene editing, whether you’re leveraging the proliferative capacity of activated T cells or harnessing the superior stemness and persistence of resting T cells, resulting in more effective and scalable cell therapies.
Flexible T Cell Workflows that Drive Innovation
Activated T Cell
Hybrid non-viral knock-out with viral knock-in
- Shortened same-day workflow
- Superior transduction efficiency
- High cell yield and viability
- Preserved CD4+/CD8+ ratio
Resting T Cell
Fully non-viral knock-out & Hybrid knock-out/knock-in
- Enhanced therapeutic potency
- Preserved stem memory
- High efficacy with lower dose requirements
- Improved safety
Start the conversation
We partner with researchers and developers to streamline your cellular engineering workflows and achieve higher yields of safe, healthy cells. We want to hear from you.
